Center for Scientific Review; Notice of Closed Meetings, 10589-10590 [2021-03525]
Download as PDF
<![CDATA[
10589
Federal Register / Vol. 86, No. 33 / Monday, February 22, 2021 / Notices
public or otherwise would be more
limited in scope than the activities such
service member, employees, contractors,
or volunteers are authorized to carry out
under this declaration.
Amendments to the Declaration,
section 2, Effective Time Period, section
XII; the sentence is corrected to read:
‘‘add to the end of the section: Liability
protections for Qualified Persons under
section V(h) of the declaration begin on
February 16, 2021, and last through
October 1, 2024.
Wilma Robinson,
Deputy Executive Secretary, U.S. Department
of Health and Human Services.
[FR Doc. 2021–03526 Filed 2–19–21; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0955–0003]
Agency Father Generic Information
Collection Request. 60-Day Public
Comment Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before April 23, 2021.
ADDRESSES: Submit your comments to
Sherrette.Funn@hhs.gov or by calling
(202) 795–7714.
FOR FURTHER INFORMATION CONTACT:
When submitting comments or
requesting information, please include
SUMMARY:
the document identifier 0955–0003–
60D, and project title for reference, to
Sherrette Funn, the Reports Clearance
Officer, Sherrette.funn@hhs.gov, or call
202–795–7714.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Generic
Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery.
Type of Collection: Father Generic
ICR.
OMB No. 0955–0003—Office of the
National Coordinator for Health
Information Technology.
Abstract: The Office of the National
Coordinator for Health Information
Technology is seeking a three-year
extension of OMB control number
0955–0003 to continue collecting
routine customer feedback on agency
service delivery. The proposed
information collection activity provides
a means to garner qualitative customer
and stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. Qualitative
feedback means information that
provides useful insights on perceptions
and opinions, and is not statistical
surveys that yield quantitative results
that can be generalized to the
population of study. This feedback will
provide insights into customer or
stakeholder perceptions, experiences,
and expectations; provide an early
warning of issues with the service; or
focus attention on areas where
communication, training, or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative,
and actionable communications
between the Agency and its customers
and stakeholders. It will also allow
feedback to contribute directly to the
improvement of program management.
The solicitation of feedback will target
areas such as timeliness,
appropriateness, accuracy of
information, courtesy, efficiency of
service delivery, and resolution of
issues with service delivery. Responses
will be assessed to plan and inform
efforts to improve or maintain the
quality of service offered to the public.
If this information is not collected, vital
feedback from customers and
stakeholders on the Agency’s services
will be unavailable.
Affected Public: Individuals,
households, professionals, and/or the
public/private sector.
Average estimates for the next three
years:
Estimated Total Number of
Respondents: 10,000.
Expected Annual Number of
Activities: 6.
Average Number of Respondents per
Activity: 1,667.
Frequency of Response: Once per
Activity.
Average Minutes per Response: 7.
Total Burden Hours: 1,167.
ANNUALIZED BURDEN HOUR TABLE
Number of
responses per
respondents
tkelley on DSKBCP9HB2PROD with NOTICES
Number of
respondents
Average
burden per
response
Total burden
hours
10,000 ..........................................................................................................................................
1
7/60
1,167
Total ......................................................................................................................................
........................
........................
1,167
Dated: February 10, 2021.
Sherrette A. Funn,
Office of the Secretary, Paperwork Reduction
Act Reports Clearance Officer.
[FR Doc. 2021–03531 Filed 2–19–21; 8:45 am]
BILLING CODE 4150–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
19:48 Feb 19, 2021
Jkt 253001
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\22FEN1.SGM
22FEN1
10590
Federal Register / Vol. 86, No. 33 / Monday, February 22, 2021 / Notices
tkelley on DSKBCP9HB2PROD with NOTICES
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Drug Discovery, Neurodegenerative
Disorders and Modeling.
Date: March 19, 2021.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Vanessa S. Boyce, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 4185,
MSC 7850, Bethesda, MD 20892, (301) 402–
3726, boycevs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: The Cancer Drug Development &
Therapeutics (CDDT).
Date: March 22–23, 2021.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lilia Topol, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–451–
0131, ltopol@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Psychopathology, Substance
Abuse, and Community-Based Interventions
Across the Lifespan.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elia K. Ortenberg, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108,
MSC 7816, Bethesda, MD 20892, (301) 827–
7189, femiaee@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Psychopathology, Substance
Abuse, and Community-Based Interventions
Across the Lifespan.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Erik Pollio, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 1006F,
Bethesda, MD 20892, 301–594–4002,
polliode@csr.nih.gov.
VerDate Sep<11>2014
19:48 Feb 19, 2021
Jkt 253001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Non-Viral Anti-Infective
Therapeutics.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bidyottam Mittra, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20894, 301.435.0000,
bidyottam.mittra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: SBIR/STTR Commercialization
Readiness Pilot (CRP) Program.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Allen Richon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6184,
MSC 7892, Bethesda, MD 20892, 301–379–
9351, allen.richon@nih.hhs.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Pulmonary Diseases.
Date: March 23–24, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: George M. Barnas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4220,
MSC 7818, Bethesda, MD 20892, 301–435–
0696, barnasg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Drug Discovery Involving the
Nervous System.
Date: March 23–24, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lai Yee Leung, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1011D
Bethesda, MD 20892, (301) 435–1042,
leungl2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–19–
326: Reducing Stigma to Improve HIV/AIDS
Prevention, Treatment and Care in Low- and
Middle-Income Countries.
Date: March 23, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Janetta Lun, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room1007E,
Bethesda, MD 20892, 301–443–3655,
janetta.lun@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–19–
326: Reducing Stigma to Improve HIV/AIDS
Prevention, Treatment and Care in Low- and
Middle-Income Countries.
Date: March 23, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marc Boulay, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
MSC 7808, Bethesda, MD 20892, (301) 300–
6541, boulaymg@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 17, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03525 Filed 2–19–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; CURE Research
Consortium Review.
Date: March 17–18, 2021.
E:\FR\FM\22FEN1.SGM
22FEN1
]]>Agencies
[Federal Register Volume 86, Number 33 (Monday, February 22, 2021)]
[Notices]
[Pages 10589-10590]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03525]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning
[[Page 10590]]
individuals associated with the grant applications, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Drug Discovery, Neurodegenerative Disorders
and Modeling.
Date: March 19, 2021.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Vanessa S. Boyce, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 4185, MSC 7850, Bethesda, MD
20892, (301) 402-3726, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: The Cancer Drug Development & Therapeutics
(CDDT).
Date: March 22-23, 2021.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lilia Topol, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892, 301-451-
0131, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Psychopathology, Substance Abuse, and
Community-Based Interventions Across the Lifespan.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elia K. Ortenberg, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108, MSC 7816, Bethesda, MD
20892, (301) 827-7189, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Psychopathology, Substance Abuse, and
Community-Based Interventions Across the Lifespan.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Erik Pollio, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institute of Health,
6701 Rockledge Drive, Room 1006F, Bethesda, MD 20892, 301-594-4002,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Non-Viral Anti-Infective Therapeutics.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bidyottam Mittra, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, Bethesda, MD 20894, 301.435.0000, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: SBIR/STTR Commercialization Readiness Pilot
(CRP) Program.
Date: March 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Allen Richon, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6184, MSC 7892, Bethesda, MD 20892, 301-379-
9351, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Pulmonary Diseases.
Date: March 23-24, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: George M. Barnas, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4220, MSC 7818, Bethesda, MD
20892, 301-435-0696, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Drug Discovery Involving the Nervous System.
Date: March 23-24, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lai Yee Leung, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 1011D Bethesda, MD 20892, (301) 435-1042,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-19-326: Reducing Stigma to Improve HIV/AIDS Prevention,
Treatment and Care in Low- and Middle-Income Countries.
Date: March 23, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Janetta Lun, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institute of Health, 6701
Rockledge Drive, Room1007E, Bethesda, MD 20892, 301-443-3655,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-19-326: Reducing Stigma to Improve HIV/AIDS Prevention,
Treatment and Care in Low- and Middle-Income Countries.
Date: March 23, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marc Boulay, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3110, MSC 7808, Bethesda, MD 20892, (301) 300-
6541, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 17, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-03525 Filed 2-19-21; 8:45 am]
BILLING CODE 4140-01-P
